PTC Therapeutics vs Sarepta Therapeutics
PTCT and SRPT side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How PTCT and SRPT compare
PTC Therapeutics is the larger company, worth 3.1 times as much as Sarepta Therapeutics ($5.3B against $1.7B).
Sarepta Therapeutics grew revenue faster over the last twelve months (−18.9% versus −35.1% for PTC Therapeutics).
Sarepta Therapeutics keeps more of each dollar of sales as profit, with a net margin of −5.9% compared with −9.2% at PTC Therapeutics.
Sarepta Therapeutics scores higher on the StockData Score (11 against 5 for PTC Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | PTCT | SRPT |
|---|---|---|
| Size and price | ||
| Market cap | $5.3B | $1.7B |
| Share price | $63.49 | $16.07 |
| Change, 1 year | −15.3% | −10.7% |
| Change, 5 years | 58.7% | −79.9% |
| Beta (5Y) | 1.09 | 0.99 |
| Employees | 991 | 835 |
| StockData Score | ||
| Total score | 5 | 11 (better) |
| Valuation score | 1 | 3 (better) |
| Growth score | 1 | 1 |
| Performance score | 2 | 3 (better) |
| Health score | 1 | 4 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 4.6× | 0.9× (better) |
| P/B | – | 1.1× |
| EV/EBITDA | 17.8× | – |
| P/FCF | 2566× | 9.6× (better) |
| FCF yield | 0.04% | 10.4% (better) |
| Fair value | $48.37 | $104.78 |
| Margin of safety | −31.3% | 84.7% (better) |
| Growth | ||
| Revenue growth (TTM) | −35.1% | −18.9% (better) |
| Revenue growth, 5Y average | 35.4% (better) | 32.4% |
| Net income growth (TTM) | −114% | – |
| EPS growth (TTM) | −114% | – |
| Profitability | ||
| Operating margin | 12.8% (better) | −2.5% |
| Net margin | −9.2% | −5.9% (better) |
| FCF margin | 0.18% | 9.0% (better) |
| Return on equity | – | −7.6% |
| Return on invested capital | – | −5.3% |
| Financial health | ||
| Debt / equity | – | 0.10 |
| Net debt / EBITDA | −7.63 | – |
| Current ratio | 3.27 | 3.46 (better) |
| Altman Z-score | 0.83 (better) | −0.22 |
| Piotroski F-score | 5 (better) | 3 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 120% | 102% |
| Held by insiders | 3.0% | 5.9% |
| Insider net buying, 12 months | −$44.2M | −$417K (better) |
| Short interest, % of float | 9.6% | 19.4% |
Go deeper
- PTCT stock overview
- PTCT income statement
- PTCT valuation and score
- SRPT stock overview
- SRPT income statement
- SRPT valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.